Publications by authors named "Tushar Kanti Sinha"
Article Synopsis
- The study aimed to assess the visual and anatomical outcomes in diabetic macular edema (DME) patients who switched from intravitreal Aflibercept (IVI AFL) to biosimilar Ranibizumab (B-RBZ) due to financial reasons rather than efficacy issues.
- A total of 57 DME patients were observed, showing substantial improvement in visual acuity during treatment with Aflibercept and a slight decline after switching to Ranibizumab, but overall vision remained better than the initial baseline.
- The transition maintained anatomical stability in terms of central macular thickness and reduced subretinal and intra retinal fluid levels, indicating that biosimilar Ranibizumab is an effective and cost-efficient therapeutic option
Introduction: This study aims to evaluate the ocular and systemic safety profiles of intravitreal biosimilar ranibizumab Ranieyes (Lupin Pharmaceuticals, Mumbai, India) in real-world clinical settings across multiple chorioretinal vascular diseases, including neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), and retinal vein occlusion (RVO) in adults.
Methods: We conducted a retrospective, consecutive, interventional, uncontrolled multicenter study using data from three hospital networks in India. A total of 1401 eyes received 2194 injections of Ranieyes between June 2022 and November 2023.
Purpose: To compare the safety and efficacy of aflibercept with brolucizumab for recalcitrant diabetic macular edema (DME).
Observations: At week 52, no significant visual improvement was noted in the eyes treated with either brolucizumab ( = 0.527) or aflibercept ( = 0.
Article Synopsis
- - This study evaluated the safety and effectiveness of using vancomycin injection as a standard preventive measure during vitreoretinal surgeries, focusing on large-scale application over 70 months.
- - A total of 31,720 procedures were analyzed, including major, minor, and silicone oil removal surgeries, with no cases of hemorrhagic occlusive retinal vasculitis or bacterial endophthalmitis reported postoperatively.
- - The findings suggest that using vancomycin in infusion fluid during these procedures is safe and beneficial in reducing the risk of post-surgery bacterial infections.
Purpose: This study investigates the efficacy of transitioning patients with neovascular age-related macular degeneration (nAMD) from aflibercept (T1) to biosimilar ranibizumab (T2), an approach not previously documented in literature.
Methods: In this multicenter observational study, patients over 50 years of age with nAMD were shifted from intravitreal aflibercept (IVI AFL) to biosimilar ranibizumab (B-RBZ) due to financial constraints. This study employed standardized ophthalmological methods to assess visual acuity (VA), central macular thickness (CMT), and subretinal and intraretinal fluid.
Purpose: To analyse outcomes of innovator ranibizumab (IRM) (Lucentis) and biosimilar ranibizumab (BRM) (Razumab) in Indian eyes with neovascular age-related macular degeneration (nAMD).
Methods: Retrospective observational study in nAMD patients, who were treated with IRM or BRM (3 loading doses followed by pro re nata (PRN). Primary outcome measures were change in best corrected visual acuity (BCVA) and central macular thickness (CMT) along with safety analysis.
Purpose: To report the 52-week real-world efficacy and safety outcomes of brolucizumab therapy for neovascular age-related macular degeneration (nAMD) in Indian eyes.
Patients And Methods: A retrospective, multicentre chart analysis of 82 eyes of 82 patients with nAMD (switch therapy: 65 eyes; treatment-naïve: 17 eyes) with 52-week follow-up data was performed. Pro-re-nata re-treatment was offered based on visual and tomographic criteria.
Article Synopsis
- The study compares the effects of innovator ranibizumab (iRBZ) and its biosimilar (bRBZ) on patients with diabetic macular edema (DME) in India, focusing on visual acuity and retinal thickness over 6 months.
- Data from patients receiving at least three injections of either treatment were analyzed, showing significant improvements in visual acuity and central macular thickness for both groups without significant differences between them.
- The results indicate that the biosimilar ranibizumab is as effective as the innovator version in treating DME, suggesting it can be a viable alternative in clinical practice.
Purpose: To evaluate the efficacy and safety of lamellar hole-associated epiretinal proliferation embedding technique with modification in the surgical management of degenerative lamellar macular hole (LMH).
Methods: There is retrospective case series of consecutive eyes who underwent pars plana vitrectomy with LHEP embedding with internal limiting membrane (ILM) inversion technique for degenerative LMH. Primary outcome measure was improvement in foveal contour and central foveal thickness (CFT).
Background/aim: To compare the intra-operative video overlay guided enlargement of Area of ILM peeled (AIP) more than three Disc Diameter (DD) versus the inverted flap technique in large (>400 µm ) Full Thickness Macular Holes (FTMH).
Methods: Retrospectively, 127 cases of large FTMHs divided into two groups (i) Group A ( = 62)-intra-operative video-overlay guided enlargement of AIP > 3DD performed and (ii) Group B ( = 65)-Inverted flap technique was done. Mean Best Corrected Visual Acuity (BCVA), hole closure rate and postoperative foveal anatomy were noted on Optical Coherence Tomography (OCT).
Purpose: To study the outcomes of submacular blood removal with isolated autologous full-thickness retinal pigment epithelial (RPE)-choroid patch graft transplantation in long-standing large-sized submacular hematomas in Indian population.
Methods: A retrospective study was done on eight consecutive patients of long-standing large-sized submacular hematoma from east India. In all cases, 23G vitrectomy was performed with the induction of retinal detachment (performed with or without 38G or 41G subretinal cannula) and a temporal 180° retinectomy was done.
Purpose: To describe innovative ways of removal of complicated difficult large retained intraocular foreign bodies (RIOFBs).
Settings: Both cases were treated at Disha Eye Hospitals, Kolkata, a tertiary eye hospital in eastern India.
Methods: Innovative approaches were taken to remove 2 difficult RIOFBs.